QQ客服 官方微博 反馈留言

	Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma
	Younes, Anas; Sehn, Laurie H.; Johnson, Peter; Zinzani, Pier Luigi; Hong, Xiaonan; Zhu, Jun; Patti, Caterina; Belada, David; Samoilova, Olga; Suh, Cheolwon
刊名	JOURNAL OF CLINICAL ONCOLOGY
	2019
卷号	37期号:15
ISSN号	0732-183X
URL标识	查看原文
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/3596394
专题	复旦大学上海医学院
推荐引用方式 GB/T 7714	Younes, Anas,Sehn, Laurie H.,Johnson, Peter,et al. Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma[J]. JOURNAL OF CLINICAL ONCOLOGY,2019,37(15).
APA	Younes, Anas.,Sehn, Laurie H..,Johnson, Peter.,Zinzani, Pier Luigi.,Hong, Xiaonan.,...&Wei, Lee-Jen.(2019).Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.JOURNAL OF CLINICAL ONCOLOGY,37(15).
MLA	Younes, Anas,et al."Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma".JOURNAL OF CLINICAL ONCOLOGY 37.15(2019).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。